Clinuvel Pharmaceuticals (ASX: CUV) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Clinuvel Pharmaceuticals Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Clinuvel Pharmaceuticals (ASX: CUV)
Latest News
Share Gainers
ALL ORDINARIES finishes higher Friday: 8 shares you missed
Share Market News
This is how ETFs are rewiring the ASX & could make or break your returns
Share Fallers
Why Costa, CLINUVEL, Ellex Medical Lasers, & Superloop dropped lower
Share Market News
ASX 200 lunch time report: NAB, Northern Star, & Sydney Airport higher
Share Market News
High profile fundie warns these 10 ASX shares have "bubble" valuations
Share Market News
Why the Clinuvel Pharmaceuticals share price is down 8% today
Share Fallers
Why Afterpay, CLINUVEL, Nearmap, & St Barbara shares dropped lower today
Share Market News
ASX 200 lunch time report: Afterpay, Nearmap, & Telstra lower
⏸️ Investing
Should you buy these 3 new ASX 200 additions?
Share Gainers
These 10 ASX 200 shares were the best-performers in FY19
Share Fallers
These were the worst-performing shares on the ASX 200 last week
Share Market News
Here are the 10 best mid-cap shares of 2019
Frequently Asked Questions
-
Yes, Clinuvel Pharmaceuticals has historically paid one unfranked shareholder dividend a year.
-
Clinuvel Pharmaceuticals generally pays its shareholder dividend in September.
-
Clinuvel Pharmaceuticals does not have a dividend reinvestment plan.
-
Clinuvel Pharmaceuticals Limited listed on the ASX on 13 February 2001.
CUV ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals Ltd (ASX: CUV) is an Australian-based global biopharmaceutical company developing drugs for the treatment of genetic and vascular disorders. Its principal product SCENESSE is a drug for an inherited disorder, erythropoietic protoporphyria, that causes an intolerance to light.
Its pioneering work aims at preventing the symptoms of skin diseases related to exposure to UV radiation and at repigmentation of the skin due to depigmentation disorders. Geographically, the company derives the majority of its revenue from its US and European markets.
